Table I.

Association between miR-150 expression and clinicopathological characteristics in patients with primary gastrointestinal diffuse large B-cell lymphoma (n=84).

		miR-150 expression level
Characteristic	Patients, n=84	Low, n=66	High, n=18	P-value
Sex				0.761
Male	44	34	10
Female	40	32	8
Age, years				0.969
≤60	33	26	7
>60	51	40	11
Tumor origin				0.759
Stomach	63	50	13
Intestinal	21	16	5
Pathological type				0.844
GCB	31	24	7
Non-GCB	53	42	11
Lugano staging status				0.029a
I–II	37	25	12
IIE-IV	47	41	6
IPI score				0.025a
0–2	41	28	13
3–5	43	38	5
ECOG score				0.002a
0–1	65	56	9
2–4	19	10	9
B symptoms				0.274
Negative	24	17	7
Positive	60	49	11
LDH level				0.064
Normal	53	45	8
Elevated	31	21	10
Treatment				0.047a
CHOP	30	20	10
R-CHOP	54	46	8
Lymph node metastasis				0.309
Negative	52	39	13
Positive	32	27	5
Bone marrow metastasis				0.759
Negative	63	49	14
Positive	21	17	4

^aP<0.05. miR, microRNA; GCB, germinal center B-cell like; IPI, International Prognostic Index; ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; CHOP, cyclophosphamide, doxorubicin, vincristine and prednisoneor; R-CHOP, CHOP-like regimen with rituximab; B symptoms, systemic symptoms such as: i) Fever of unknown origin exceeding 38°C for 3 consecutive days; ii) unexplained weight loss of >10% within 6 months; iii) night sweats.